Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
作者信息
Yee T T, Lee C A
出版信息
Thromb Haemost. 1999 May;81(5):852.
PMID:10365768
Abstract
摘要
相似文献
1
Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Thromb Haemost. 1999 May;81(5):852.
2
Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Thromb Haemost. 1998 Dec;80(6):1036-7.
3
Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
Thromb Haemost. 1999 Mar;81(3):475-6.
4
Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
Thromb Haemost. 1999 May;81(5):723-6.
5
Inhibitor development in a multitransfused patient with severe haemophilia A.
Thromb Haemost. 1999 Jul;82(1):151-2.
6
Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
Thromb Haemost. 2000 Oct;84(4):733-4.
7
Inhibitors in young boys with haemophilia.
Baillieres Best Pract Res Clin Haematol. 2000 Sep;13(3):457-68. doi: 10.1053/beha.2000.0088.
8
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Am J Hematol. 2004 Dec;77(4):346-50. doi: 10.1002/ajh.20204.
9
The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
Semin Hematol. 1993 Apr;30(2 Suppl 1):22-7.
10
Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
Haematologica. 2000 Oct;85(10 Suppl):113-6.
Zotero 插件